US Merger & Acquisition SEC Filings — May 12, 2026

12-05-2026

On May 6, 2026, Ashford Hospitality Trust, Inc. completed the sale of the 150-room Embassy Suites Dallas Near the Galleria for approximately $16.6 million in cash net of selling expenses, while paying approximately $16.0 million to the mortgage lender secured by ten hotels including the sold property. Pro forma consolidated balance sheet as of December 31, 2025 shows total assets declining to $2,821,132 thousand from $2,833,632 thousand and net hotel properties decreasing to $2,072,954 thousand from $2,085,244 thousand. Pro forma statement of operations for the year ended December 31, 2025 reflects total revenue declining to $1,098,114 thousand from $1,104,388 thousand due to removal of the hotel's $6,274 thousand revenue, but net income loss improving to $(180,552) thousand from $(188,159) thousand, and loss per share to $(34.73) from $(35.99).

• · Pro forma adjustments include $16,618 thousand cash received net of $423 thousand working capital and $15,998 thousand mortgage repayment.
• · Embassy Suites Dallas contributed $6,274 thousand total hotel revenue but $(3,284) thousand net loss for the year ended Dec 31, 2025.
• · The mortgage loan is secured by ten hotels including the sold property.
• · Pro forma gain on disposition of $4,323 thousand (preliminary, with related tax effects).

12-05-2026

Mereo BioPharma reported Q1 2026 net loss of $6.7 million, an improvement from $12.9 million in Q1 2025, driven by a $3.3 million decrease in G&A expenses to $4.0 million despite a $0.8 million increase in R&D expenses to $4.7 million. Cash and cash equivalents totaled $36.2 million as of March 31, 2026, down from $41.0 million at year-end 2025, providing runway into mid-2027. Setrusumab Phase 3 studies (Orbit and Cosmic) missed primary endpoints on fracture rate reduction but met key secondary endpoints on bone mineral density and PROs, leading to initiated regulatory discussions; alvelestat partnership talks and vantictumab Phase 2 plans (H2 2026) continue.

• · Setrusumab Phase 3 studies achieved high statistical significance on key secondary endpoint of bone mineral density improvement and reductions in vertebral fractures.
• · Alvelestat Phase 3 anticipated to enroll ~220 patients with independent primary endpoints: SGRQ Total Score (US) and lung density by CT (Europe).
• · āshibio to fund global vantictumab program and holds ex-Europe commercialization rights; Mereo retains EU/UK rights.

12-05-2026

Collegium Pharmaceutical completed the acquisition of AZSTARYS from Corium Therapeutics for approximately $650 million in cash, funded by $350 million of existing cash and $300 million from a delayed draw term loan, with up to $135 million in additional milestone payments, adding a complementary ADHD product expected to generate $60 to $70 million in net revenue for the remainder of 2026 and patent protection through December 2037. The company raised its 2026 full-year guidance to $865 to $895 million in total Product Revenues, Net (previously $805 to $825 million) and $475 to $500 million in Adjusted EBITDA (previously $455 to $475 million), with JORNAY PM guidance unchanged at $190 to $200 million and expected synergies exceeding $50 million annually within 12 months. However, Chief Commercial Officer Scott Dreyer will depart effective end of August 2026, and Chief Medical Officer Thomas Smith, M.D., will depart following a transition period.

• · AZSTARYS supported by six Orange Book-listed patents, most expiring December 2037
• · AZSTARYS expected net revenue $60 to $70 million for remainder of 2026

12-05-2026

Healthcare AI Acquisition Corp., a SPAC, issued an interest-free promissory note for $196,919.23 to Leading Group Limited on May 6, 2026, for working capital, with $156,474 allocated to extension payments and $40,445.23 to general expenses including legal fees. The note is repayable upon consummation of a business combination, termination of the merger agreement, liquidation, or October 14, 2026. No operational performance metrics or period comparisons are provided.

• · Note includes trust account waiver, confirming no recourse to trust assets except for specific claims outside trust.
• · Governed by New York law with exclusive jurisdiction in New York courts.
• · Signed by Jiande Chen for Maker and Zhang Li for Payee.

12-05-2026

Inception Growth Acquisition Limited, a blank check company (SPAC), deposited $12,203.33 into its Trust Account on May 11, 2026, to extend the deadline for completing a business combination by one month, from May 13, 2026, to June 13, 2026. This extension avoids immediate liquidation and provides additional time to pursue a merger, capital stock exchange, asset acquisition, or similar transaction. The company issued a press release on May 12, 2026, announcing the contribution.

• · Filing date: May 12, 2026
• · Event date: May 11, 2026
• · Trust Account extension: from May 13, 2026 to June 13, 2026 (additional 1 month)
• · Company address: 875 Washington Street, New York, NY 10014
• · Trading on: OTC Markets Group, Inc.

12-05-2026

Alpha and Omega Semiconductor Limited completed the sale of approximately 20.3% of the outstanding equity interest in its joint venture for power semiconductor packaging, testing, and 12-inch wafer fabrication in Chongqing, China, to SIMIC Holdings Co., Ltd. The aggregate cash consideration of $150 million was fully received in four installments, with the final payment on May 11, 2026. The transaction is not significant under Rule 11-01(b)(2) of Regulation S-X, so no pro forma financial statements are provided.

• · Equity transfer agreement originally entered on July 14, 2025
• · Agreement filed as exhibit to Form 10-Q for quarter ended September 30, 2025 (filed November 6, 2025)

12-05-2026

Quetta Acquisition Corporation received Nasdaq approval on May 12, 2026, to transfer its ordinary shares (QETA), units (QETAU), and rights (QETAR) from the Nasdaq Global Market to the Nasdaq Capital Market, effective at market open on May 14, 2026, maintaining the same trading symbols. This transfer resolves the company's prior non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement, with Nasdaq confirming full compliance with all continued listing standards and cancelling the scheduled hearings panel review.

• · Previous Nasdaq delisting notice issued April 6, 2026, for MVLS non-compliance, with hearing requested.
• · Company's principal executive offices: 1185 Avenue of the Americas, Suite 304, New York, NY 10036; Phone: (212) 612-1400.
• · Emerging growth company status confirmed.

12-05-2026

Ameresco, Inc. (NYSE: AMRC) announced the closing of its joint venture, Neogenyx Fuels, with HA Sustainable Infrastructure Capital, Inc. (NYSE: HASI), where Ameresco owns 70% and HASI owns 30%, contributing its biofuels business valued at a $1.8 billion post-money enterprise value. HASI committed $400 million to the JV, with $100 million distributed to Ameresco at closing. The transaction supports growth in advanced biofuels, and Ameresco reaffirmed its FY26 guidance from the May 4, 2026 earnings call.

• · Ameresco founded in 2000 and headquartered in Framingham, MA
• · Additional transaction details in Company’s Current Reports on Form 8-K filed with the SEC

12-05-2026

Plains All American Pipeline, L.P. (PAA) and Plains GP Holdings (PAGP) completed the sale of Plains Midstream Canada ULC, owning substantially all of PAA’s Canadian natural gas liquids (NGL) business, to Keyera Corp. for approximately $3.3 billion in net cash proceeds. The proceeds will repay outstanding indebtedness and support general partnership purposes, with post-closing leverage expected to trend toward the middle of the 3.25 to 3.75x target range. The transaction positions Plains as a pure-play crude oil midstream company with more durable free cash flow, reduced maintenance capital, and lower corporate taxes.

• · Definitive Share Purchase Agreement (SPA) dated June 17, 2025
• · No special distribution anticipated post-closing due to tax mitigation from bonus depreciation on Cactus III acquisition
• · Leverage target range: 3.25 to 3.75x

12-05-2026

Plains All American Pipeline, L.P. (PAA) and Plains GP Holdings (PAGP) completed the sale of all shares in Plains Midstream Canada ULC, owning substantially all of PAA’s Canadian natural gas liquids (NGL) business, to Keyera Corp. pursuant to a Share Purchase Agreement dated June 17, 2025. Net cash proceeds were approximately $3.3 billion, to be used for repaying indebtedness and general partnership purposes, with post-closing leverage expected to trend toward the middle of the 3.25-3.75x target range. The transaction transforms Plains into a pure play crude oil midstream company with reduced commodity price volatility, lower maintenance capital, and lower corporate taxes; no special distribution is anticipated due to tax mitigation from the Cactus III acquisition.

• · Share Purchase Agreement dated June 17, 2025
• · Target leverage ratio range: 3.25 to 3.75x
• · No special distribution to unitholders due to tax mitigation via bonus depreciation

12-05-2026

Global Asset Management Group, Inc. (GAMG)'s subsidiary RI Property Holdings, Inc. completed the acquisition of the remaining 83.125% membership interest in Memorial Real Estate Group LLC (MREG) for total consideration of $6,455,000 ($455,000 cash down payment + $6,000,000 GAMG convertible note), achieving 100% ownership of MREG, which holds title to the Memorial Hospital property in Pawtucket, RI. Concurrently, GAMG assumed $10,000,000 MREG debt via assignment and senior liens totaling approximately $1,493,000, including a $1,019,455 CNE first mortgage and third-party mechanic's liens. While this provides full control without a deed transfer, it involves significant assumed liabilities with no disclosed property valuation or operational metrics.

• · GAMG convertible note terms: 6% simple interest, matures April 8, 2027; convertible at holder's discretion after October 8, 2026 at 90% of 30-day VWAP.
• · No deed transfer required; MREG retains record title to Memorial Hospital property subject to assumed liens.
• · Closing deliverables include membership interest assignment, amended MREG operating agreement, debt assignment, and GAMG convertible note.
• · FVP Servicing, LLC resigns as administrative agent post-assignment.
• · Governing law: State of Wyoming.

12-05-2026

WinVest Acquisition Corp., a SPAC, effected the third $30,000 drawdown under its $180,000 unsecured, interest-free promissory note with sponsor WinVest SPAC LLC on May 10, 2026, to deposit funds into the trust account and extend the Termination Date for consummating an initial business combination from May 17, 2026, to June 17, 2026. The note allows up to six equal $30,000 drawdowns and matures upon business combination closing or liquidation, with repayment only from amounts outside the trust account if no combination occurs. This routine extension provides additional time but increases off-balance sheet obligations reliant on sponsor funding.

• · Promissory note issued on March 16, 2026, drawable in up to six equal $30,000 amounts.
• · Funds from drawdown deposited into trust account for distribution to public shareholders upon liquidation or redemption in connection with business combination.
• · All securities trade on OTC Markets Group Inc.